Editorial: GPCR in Inflammatory and Cancer Diseases

Front Endocrinol (Lausanne). 2020 Sep 25:11:588157. doi: 10.3389/fendo.2020.588157. eCollection 2020.

Authors

Alain Couvineau¹, Rosa P Gomariz², Yossan-Var Tan³

Affiliations

¹ INSERM UMR1149/Inflammation Research Center (CRI), Team "From Inflammation to Cancer in Digestive Diseases" Labeled by "la Ligue Nationale contre le Cancer", University of Paris, DHU UNITY, Paris, France.
² Department of Cell Biology, Faculty of Biology and Medicine, Complutense University of Madrid, Madrid, Spain.
³ University of Rouen Normandy, INSERM U1234 PANTHER, IRIB, Rouen University Hospital, Department of Immunology and Biotherapy, Rouen, France.

No abstract available

Keywords: GPCR; cancer; inflammation; neurodegenerative diseases; neuropeptides.

Publication types

Editorial
Introductory Journal Article

MeSH terms

Angiotensin-Converting Enzyme 2 / metabolism
Arthritis, Rheumatoid / metabolism
Autoimmune Diseases / metabolism
Drug Combinations
Gastrointestinal Neoplasms* / metabolism
Humans
Inflammation / metabolism
Inflammatory Bowel Diseases / metabolism
Neurodegenerative Diseases / metabolism
Phentolamine / pharmacology
Phentolamine / therapeutic use
Receptors, G-Protein-Coupled* / antagonists & inhibitors
Receptors, G-Protein-Coupled* / metabolism
Vasoactive Intestinal Peptide / pharmacology
Vasoactive Intestinal Peptide / therapeutic use

Substances

ACE2 protein, human
Angiotensin-Converting Enzyme 2
aviptadil
Drug Combinations
Phentolamine
Receptors, G-Protein-Coupled
Vasoactive Intestinal Peptide